Overview

Efficacy of QAX576 in Asthma

Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the efficacy of 24 weeks intravenous treatment with QAX576 in patients with persistent asthma not adequately controlled with inhaled corticosteroids and long acting beta2-agonists.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals